Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Patent number: 7955604
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: June 7, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • Patent number: 7943375
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: May 17, 2011
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W. Barnett, Jan zur Megede
  • Publication number: 20110110982
    Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.
    Type: Application
    Filed: October 18, 2010
    Publication date: May 12, 2011
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Guido Grandi, Immaculada Margarit Y. Ros, Cira Daniela Rinaudo, Domenico Maione
  • Patent number: 7939539
    Abstract: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: May 10, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Liana M. Lagniton, Ryan N. Constantine, Manoj C. Desai
  • Patent number: 7939087
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: May 10, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • Patent number: 7935805
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: May 3, 2011
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan Barnett, Jan Zur Megede
  • Publication number: 20110091472
    Abstract: CD40 antagonists are used to prepare compositions, including pharmaceutical compositions, for treating autoimmune and neoplastic diseases in a mammal. The CD40 antagonist compositions are useful for reversing or substantially diminishing such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and psoriasis.
    Type: Application
    Filed: December 27, 2010
    Publication date: April 21, 2011
    Applicant: Novartis Vaccines and Diagnostic, Inc.
    Inventors: Keting Chu, Changyu Wang
  • Patent number: 7927839
    Abstract: West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: April 19, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Venkatakrishna Shyamala
  • Patent number: 7919246
    Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: April 5, 2011
    Assignees: Novartis Vaccines and Diagnostics, Inc., Sagres Discovery, Inc.
    Inventors: Albert Lai, Abdallah Fanidi, Robert Booher, Christin Tse, Xie Xu, Guoying Yu, Edward Moler, Michael Rowe
  • Publication number: 20110065146
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Application
    Filed: April 30, 2010
    Publication date: March 17, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Susan W. Barnett, Jan zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
  • Publication number: 20110052632
    Abstract: The present disclosure relates to novel polynucleotides that encode HIV Env polypeptides. In particular, the disclosure relates to sequences derived from HIV strain Botswana MJ4 encoding Env polypeptides. Compositions comprising these polynucleotides and methods of using these polynucleotides are also disclosed.
    Type: Application
    Filed: November 10, 2010
    Publication date: March 3, 2011
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: YING LIAN, Jan Zur Megede, Indresh Srivastava, Susan W. Barnett
  • Patent number: 7897155
    Abstract: Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: March 1, 2011
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Daniela Tornese Buonamassa, Catherine E. Greer, Cesira L. Galeotti, Giuliano Bensi, Roberto Petracca
  • Publication number: 20110045017
    Abstract: This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection.
    Type: Application
    Filed: November 8, 2010
    Publication date: February 24, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: YING LIAN, JAN ZUR MEGEDE, INDRESH SRIVASTAVA, SUSAN W. BARNETT
  • Patent number: 7893219
    Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for ?-1,6-glucan.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: February 22, 2011
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Antonio Cassone, Antonella Torosantucci
  • Patent number: 7893096
    Abstract: The invention provides immunostimulatory compositions comprising a small molecule immuno-poteniator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: February 22, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Nicholas M. Valiante, Jr.
  • Patent number: 7888004
    Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 15, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
  • Publication number: 20110033456
    Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
    Type: Application
    Filed: September 27, 2010
    Publication date: February 10, 2011
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Keting Chu, Lorianne K. Masuoka
  • Publication number: 20110020352
    Abstract: Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.
    Type: Application
    Filed: June 21, 2010
    Publication date: January 27, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Pablo D. GARCIA, Stephen F. HARDY, Jaime ESCOBEDO, Lewis T. WILLIAMS
  • Publication number: 20110020396
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Application
    Filed: August 19, 2010
    Publication date: January 27, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Susan Barnett, Indresh Srivastava
  • Patent number: 7875624
    Abstract: Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: January 25, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Carla Heise, Sang H. Lee